Table 1.
Novel experimental investigations of hydrogen against the ocular pathologies (up to December 2015)
| Animals | Disease models | Human diseases | HRS Delivery approach | Time and investigator |
|---|---|---|---|---|
| Rat | Retinal light damage | RD | IP injection | Tian et al51 |
| Rat | Retinal light damage | RD | IP injection | Feng et al50 |
| Rat | STZ induced retinopathy | DR | IP injection | Xiao et al56 |
| Rat | STZ induced retinopathy | DR | IP injection | Feng et al57 |
| Mouse | Hyperoxia induced retinopathy | DR | IP injection | Huang et al60 |
| Rat | Optic nerve crush | TON | IP injection | Sun et al64 |
| Rat | Selenite induce cataract | Cataract | IP injection | Yang et al23 |
| Rat | Retinal I/R injury | Glaucoma | Topical drops | Oharazawa et al39 |
| Rat | Retinal I/R injury | Glaucoma | IP injection | Liu et al77 |
| Guinea pig | Glutamine induced retinopathy | Glaucoma | IP and IV injection | Wei et al38 |
| Mouse | Cornea alkali-burn | Corneal neovascularization | Topical irrigation | Kubota et al71 |
Abbreviations: HRS, hydrogen rich saline; RD, retinal degeneration; DR, diabetic retinopathy; TON, traumatic optic neuropathy; IP, intraperitoneal injection; IV, intravitreous injection; STZ, streptozotocin.